Immunocore

IMCRNasdaq United Kingdom Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$1.670 B

$32.42 +0.75%

Close of 22 Sept 2026

Revenue

$400.0M

#2017 by revenue

Earnings

-$35.5M

Loss-making

Shares outstanding

51,498,617

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#38NovavaxNVAX$1.79B
#39Taysha Gene TherapiesTSHA$1.68B
#40ImmunocoreIMCR$1.67B
#41Inhibrx BiosciencesINBX$1.63B
#42Maze TherapeuticsMAZE$1.58B

What if Immunocore were worth as much as…

Open the what-if tool →

Gold $30.2T

$587,083.14

Per share 18,109× higher

Bitcoin $1.74T

$33,819.45

Per share 1,043× higher

Nvidia $5.52T

$107,105.15

Per share 3,304× higher

Or at a round number

$5.00B $10.0B $20.0B $50.0B

Where these numbers come from

Share counts and financials for Immunocore are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.